\-\ Texto\\:\\ \ \(0\)\
\-\ vitals\\:\\ afebrile\\,\\ hr\\ 82\\,\\ rr\\ 15\\,\\ bp\\ 142\\/89\\,\\ o2\\ sat\\ 97\\%\\ ra\ \(0\)\
\-\ pe\\:\ \(6\)\
\-\ gen\\:\\ anxious\\-appearing\\ male\\ in\\ mild\\ discomfort\ \(0\)\
\-\ heent\\:\\ eomi\\,\\ no\\ pharyngeal\\ erythema\ \(0\)\
\-\ cardiac\\:\\ rrr\\,\\ no\\ murmurs\\,\\ rubs\\ or\\ gallops\\,\\ normal\\ s1\\/s2\ \(0\)\
\-\ lungs\\:\\ cta\\ bilaterally\ \(0\)\
\-\ abd\\:\\ mild\\ diffuse\\ tenderness\\ to\\ palpation\\,\\ no\\ rebound\\ tenderness\\,\\ bs\\ x\\ 4\ \(0\)\
\-\ ext\\:\\ ttp\\ with\\ palpable\\ swelling\\ lateral\\ left\\ 10th\\ rib\ \(0\)\
\-\ labs\\:\ \(4\)\
\-\ wbc\\ 14\\.5\\ \\(no\\ left\\ shift\\)\ \(0\)\
\-\ bun\\ 35\\,\\ cr\\ 1\\.9\\,\\ \\(\\+\\)\\ microscopic\\ hematuria\ \(0\)\
\-\ ca\\ 8\\.2\ \(0\)\
\-\ rcc\\â\\€\\™s\\ are\\ usually\\ resistant\\ to\\ chemotherapy\\ and\\ radiation\\ with\\ the\\ best\\ likelihood\\ of\\ cure\\ being\\ surgical\\ resection\\ \\(radical\\ vs\\.\\ partial\\ nephrectomy\\)\\.\\ \\ unresectable\\ rcc\\â\\€\\™s\\ have\\ a\\ \\<20\\%\\ 5\\-year\\ survival\\ rate\\.\\ \\ cryoprotective\\ nephrectomy\\ can\\ be\\ utilized\\ in\\ patients\\ in\\ good\\ status\\ with\\ metastatic\\ primary\\ disease\\.\\ \\ other\\ options\\ include\\ arterial\\ tumor\\ embolization\\,\\ hormone\\ therapy\\ and\\ immunotherapy\\.\\ \\ infrequent\\ but\\ reproducible\\ responses\\ have\\ been\\ noted\\ to\\ a\\-interferon\\ and\\ il\\-2\\ therapy\\ in\\ combination\\ with\\ anti\\-angiogenic\\ chemotherapy\\.\\ \\ five\\-year\\ survival\\ is\\ 90\\-100\\%\\ when\\ tumor\\ is\\ confined\\ to\\ the\\ renal\\ capsule\\ but\\ drops\\ to\\ \\<50\\%\\ when\\ the\\ capsule\\ has\\ been\\ invaded\\.\\ \\ metastatic\\ disease\\ to\\ local\\ or\\ distant\\ lymph\\ nodes\\ results\\ in\\ a\\ 10\\-15\\%\\ 5\\-year\\ survival\\.\ \(0\)\
\-\ \\â\\€\\¢\\ pa\\ and\\ lateral\\ chest\\ radiograph\ \(0\)\
\-\ 1\\)\\ lytic\\ bone\\ lesions\\ of\\ the\\ right\\ posterior\\ 3rd\\ rib\\ and\\ left\\ lateral\\ 10th\\ rib\\ with\\ associated\\ soft\\ tissue\\ masses\\ likely\\ to\\ represent\\ metastatic\\ disease\\.\ \(0\)\
\-\ \\â\\€\\¢\\ bone\\ scan\\:\ \(0\)\
\-\ 1\\)\\ areas\\ of\\ photopenia\\ with\\ subtle\\ regions\\ of\\ increased\\ activity\\ at\\ left\\ antero\\-lateral\\ 10th\\ rib\\ and\\ right\\ posterior\\ 3rd\\ rib\\.\\ \\ cannot\\ exclude\\ metastatic\\ disease\\.\ \(0\)\
\-\ 2\\)poorly\\ visualized\\ right\\ renal\\ upper\\ pole\\ \\-\\ unable\\ to\\ exclude\\ pathologic\\ abnormality\\.\\ \\ \ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ \\â\\€\\¢\\ ct\\ thorax\\/abdomen\\ with\\ iv\\ and\\ po\\ contrast\\:\ \(0\)\
\-\ 1\\)\\ heterogeneous\\ mass\\ involving\\ the\\ superior\\ pole\\ of\\ the\\ right\\ kidney\\ consistent\\ with\\ area\\ of\\ photopenia\\ on\\ bone\\ scan\\ concerning\\ for\\ rcc\\.\\ \\ accompanying\\ right\\ adrenal\\ mass\\ and\\ expansile\\ destructive\\ lytic\\ lesions\\ left\\ 10th\\ rib\\ and\\ right\\ 3rd\\ rib\\ concerning\\ for\\ metastasis\\.\\ \\ \\ multiple\\ low\\ attenuating\\ cystic\\ structures\\ noted\\ throughout\\ the\\ bilateral\\ kidneys\\ consistent\\ with\\ renal\\ cysts\\.\ \(0\)\
\-\ renal\\ cell\\ carcinoma\\ with\\ lytic\\ metastasis\ \(0\)\
\-\ renal\\ cell\\ carcinoma\\ \ \(22\)\
\-\ angiomyolipoma\ \(35\)\
\-\ collecting\\ duct\\ carcinoma\ \(1\)\
\-\ hemorrhagic\\ cyst\ \(15\)\
\-\ infected\\ cyst\ \(1\)\
\-\ lymphoma\ \(373\)\
\-\ mets\ \(38\)\
\-\ oncocytoma\ \(13\)\
\-\ abscess\ \(594\)\
\-\ transitional\\ cell\\ carcinoma\ \(13\)\
\-\ differential\\ dx\\ cold\\ lesion\\ on\\ bone\\ scintigraphy\\:\ \(0\)\
\-\ metastasis\\-\\ renal\\,\\ thyroid\\,\\ breast\\,\\ lung\ \(0\)\
\-\ myeloma\ \(71\)\
\-\ infarct\\ \\(early\\)\ \(0\)\
\-\ radiation\\ tx\ \(2\)\
\-\ bone\\ cyst\ \(88\)\
\-\ prostheses\\ or\\ attenuation\\ artifacts\ \(0\)\
\-\ children\\-\\ consider\\ infection\\ and\\ neuroblastoma\ \(0\)\
\-\ 70\\ y\\.o\\.\\ hispanic\\ male\\ presents\\ to\\ ed\\ with\\ luq\\ pain\\,\\ fever\\,\\ chills\\ and\\ diaphoresis\\ s\\/p\\ return\\ from\\ vacation\\ to\\ mexico\\.\\ hx\\ of\\ documented\\ lytic\\ lesion\\ left\\ 10th\\ rib\\ and\\ right\\ 3rd\\ rib\\ on\\ ct\\ scan\\ 1\\ yr\\ prior\\.\\ \\ notes\\ weight\\ loss\\ x\\ 1\\ year\\.\\ denies\\ night\\ sweats\\.\ \(0\)\
\-\ denies\\ nausea\\ or\\ vomiting\\.\\ no\\ hematemesis\\ or\\ hematochezia\\/melena\\.\ \(0\)\
\-\ renal\\ cell\\ carcinoma\\ is\\ the\\ most\\ common\\ primary\\ renal\\ tumor\\ in\\ adults\\ \\(85\\%\\)\\ and\\ accounts\\ for\\ 2\\%\\ of\\ all\\ malignancies\\.\\ \\ risk\\ factors\\ include\\ increased\\ age\\ \\(50\\-70\\)\\,\\ smoking\\ history\\ \\(dose\\-dependent\\)\\,\\ male\\,\\ cadmium\\/benzene\\/asbestos\\ exposure\\,\\ chronic\\ dialysis\\,\\ excessive\\ phenacetin\\ ingestion\\ and\\ hereditary\\ genetic\\ predispositions\\.\\ \\ bilateral\\ rcc\\â\\€\\™s\\ are\\ more\\ common\\ in\\ von\\ hippel\\-lindau\\,\\ tuberous\\ sclerosis\\ and\\ familial\\ rcc\\,\\ however\\ bilateral\\ disease\\ occurs\\ in\\ only\\ 2\\%\\ of\\ patients\\.\\ unilateral\\ disease\\ is\\ multi\\-centric\\ in\\ 25\\%\\ of\\ all\\ diagnosed\\.\\ \\ \ \(0\)\
\-\ malignant\\ cells\\ arise\\ from\\ the\\ proximal\\ tubular\\ epithelium\\ and\\ are\\ located\\ in\\ the\\ renal\\ cortex\\ with\\ multiple\\ pathologic\\ subtypes\\ to\\ include\\ clear\\ cell\\ \\(75\\%\\)\\,\\ papillary\\,\\ granular\\ and\\ collecting\\ duct\\ carcinoma\\.\\ \\ imaging\\ often\\ reveals\\ the\\ heterogeneity\\ of\\ these\\ tumors\\ ranging\\ from\\ completely\\ cystic\\ to\\ solid\\.\\ staging\\ can\\ be\\ accomplished\\ with\\ either\\ the\\ tnm\\ \\(tumor\\,\\ node\\,\\ metastasis\\)\\ system\\ or\\ the\\ robson\\ criteria\\:\ \(0\)\
\-\ tnm\\ guidelines\\ \\-\\ considered\\ to\\ be\\ more\\ precise\\ due\\ to\\ clear\\ definition\\ of\\ anatomic\\ extent\\ of\\ the\\ tumor\ \(0\)\
\-\ \\â\\€\\¢\\ stage\\ 1\\ rccs\\ are\\ 7\\ cm\\ or\\ smaller\\ and\\ confined\\ to\\ the\\ kidney\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ stage\\ 2\\ rccs\\ are\\ larger\\ than\\ 7\\ cm\\ but\\ still\\ organ\\ confined\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ stage\\ 3\\ is\\ subdivided\\ into\\ three\\ groups\\:\ \(0\)\
\-\ \\ \\ \\-\\ t3a\\ involves\\ perinephric\\ fat\ \(0\)\
\-\ \\ \\ \\-\\ t3b\\ extension\\ into\\ the\\ renal\\ vein\\ or\\ vena\\ cava\\,\\ involve\\ the\\ ipsilateral\\ adrenal\\ gland\\,or\\ have\\ spread\\ to\\ one\\ local\\ lymph\\ node\\.\\ \ \(0\)\
\-\ \\ \\ \\-\\ t3c\\ tumor\\ involves\\ infradiaphragmatic\\ ivc\ \(0\)\
\-\ \\â\\€\\¢\\ stage\\ 4\\ tumors\\ extend\\ beyond\\ the\\ gerota\\ fascia\\,\\ to\\ more\\ than\\ one\\ local\\ node\\ or\\ have\\ distant\\ metastases\ \(0\)\
\-\ robson\\ criteria\ \(0\)\
\-\ i\\ \\ tumor\\ confined\\ within\\ the\\ renal\\ capsule\\.\\ \ \(0\)\
\-\ ii\\ invasion\\ into\\ perinephric\\ fat\\ but\\ contained\\ within\\ the\\ gerota\\ fascia\\ \\(involvement\\ of\\ ipsilateral\\ adrenal\\ gland\\)\\.\\ \ \(0\)\
\-\ iiia\\ invasion\\ of\\ renal\\ vein\\ or\\ ivc\\ \\(w\\ or\\ w\\/o\\ venous\\ thrombus\\)\ \(0\)\
\-\ iiib\\ regional\\ lymph\\ node\\ involvement\ \(0\)\
\-\ iiic\\ invasion\\ of\\ both\\ renal\\ vein\\/ivc\\ and\\ regional\\ lymph\\ nodes\ \(0\)\
\-\ iva\\ direct\\ invasion\\ of\\ adjacent\\ organs\\ \ \(0\)\
\-\ ivb\\ distant\\ metastases\ \(0\)\
\-\ renal\\ cell\\ carcinoma\\ is\\ diagnosed\\ incidentally\\ in\\ 50\\%\\ of\\ cases\\ and\\ often\\ presents\\ with\\ flank\\ pain\\,\\ mass\\,\\ hematuria\\ \\(gross\\ vs\\.\\ microscopic\\)\\ or\\ noted\\ on\\ imaging\\.\\ \\ secondary\\ findings\\ include\\ weight\\ loss\\,\\ fever\\,\\ hypertension\\,\\ hypercalcemia\\ and\\ a\\ variety\\ of\\ paraneoplastic\\ syndromes\\.\\ \\ ct\\ is\\ the\\ most\\ valuable\\ imaging\\ modality\\ to\\ confirm\\ size\\ and\\ involvement\\ of\\ local\\ structures\\ with\\ 91\\%\\ accuracy\\ in\\ staging\\.\\ \\ \ \(0\)\
\-\ bosniak\\ guidelines\\ for\\ evaluation\\ of\\ cystic\\ renal\\ masses\\ on\\ ct\ \(0\)\
\-\ i\\)\\ simple\\,\\ benign\\ cysts\\ with\\ homogeneity\\,\\ water\\ density\\ and\\ a\\ sharp\\ interface\\ without\\ wall\\ thickness\\,\\ calcification\\ or\\ enhancement\ \(0\)\
\-\ ii\\)\\ cystic\\ with\\ one\\/two\\ thin\\ septations\\,\\ thin\\/fine\\ calcifications\\ and\\ hyperdense\\ benign\\ lesions\ \(0\)\
\-\ iif\\)\\ need\\ f\\/u\\ secondary\\ to\\ minimally\\ complicated\\ cysts\ \(0\)\
\-\ iii\\)\\ indeterminate\\ cystic\\ masses\\ requiring\\ surgical\\ evaluation\\ due\\ to\\ wall\\ thickness\\,\\ nodularity\\,\\ thick\\/\\ irregular\\ peripheral\\ calcifications\\ with\\ multilocular\\ enhancing\\ septa\ \(0\)\
\-\ iv\\)\\ non\\-uniform\\,\\ thick\\,\\ enhancing\\ wall\\ with\\ large\\ nodules\\ and\\ solid\\ components\\.\ \(0\)\
\-\ often\\ appears\\ as\\ a\\ heterogeneous\\ exophytic\\ mass\\ with\\ distortion\\ of\\ the\\ renal\\ contour\\ secondary\\ to\\ hemorrhage\\ and\\ necrosis\\.\\ \\ metastatic\\ disease\\ involves\\ direct\\ local\\ invasion\\ of\\ the\\ adrenal\\ glands\\,\\ liver\\,\\ spleen\\,\\ colon\\ and\\ pancreas\\ with\\ local\\ lymphadenopathy\\.\\ \\ rcc\\â\\€\\™s\\ can\\ extend\\ into\\ the\\ renal\\ vein\\ and\\ ultimately\\ the\\ ivc\\ resulting\\ in\\ thrombosis\\.\\ \\ the\\ lungs\\ as\\ the\\ \\#1\\ site\\ for\\ distant\\ metastasis\\.\\ skeletal\\ lesions\\ are\\ purely\\ lytic\\ in\\ nature\\,\\ well\\-defined\\ as\\ a\\ focal\\ photopenic\\ defect\\ on\\ technetium\\ 99m\\ mdp\\ bone\\ scan\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\)\\ older\\,\\ robert\\ and\\ resnick\\,\\ martin\\.\\ diagnosis\\ of\\ genitourinary\\ disease\\.\\ thieme\\:\\ 1997\\.\ \(0\)\
\-\ 2\\)\\ pollack\\,\\ m\\.\\ howard\\ et\\ al\\.\\ clinical\\ urography\\,\\ 2nd\\ ed\\.\\ vol\\ 2\\ w\\.b\\.\\ saunders\\ company\\:\\ philadelphia\\,\\ 2000\\ \ \(0\)\
\-\ 3\\)\\ weissleder\\,\\ ralph\\ et\\ al\\.\\ primer\\ of\\ diagnostic\\ imaging\\,\\ 2nd\\ ed\\.\\ mosby\\:\\ philadelphia\\,\\ 1997\\ brant\\ we\\,\\ helms\\ ca\\.\\ fundamentals\\ of\\ diagnostic\\ radiology\\.\\ 2nd\\ ed\\.\\ philadelphia\\:\\ lippincott\\ williams\\ and\\ wilkins\\.\\ 1999\\.\ \(0\)\
\-\ 4\\)\\ rugo\\ hope\\ s\\,\\ \\"oncology\\"\\ \\(chapter\\)\\.\\ mcphee\\ sj\\,\\ papadakis\\ ma\\,\\ tierney\\ lm\\,\\ jr\\.\\:\\ current\\ medical\\ diagnosis\\ \\&\\ treatment\\ 2008\ \(0\)\
\-\ 5\\)\\ sheth\\,\\ sheila\\ et\\ al\\.\\ \\â\\€\\œcurrent\\ concepts\\ in\\ the\\ diagnosis\\ and\\ management\\ of\\ renal\\ cell\\ carcinoma\\:\\ role\\ of\\ multidector\\ ct\\ and\\ three\\-dimensional\\ ct\\.\\â\\€\\\\ radiographics\\ 2001\\;\\ 21\\:\\ s237\\-\\ s254\\.\\ \ \(0\)\
\-\ 6\\)\\ cotran\\ rs\\,\\ kumar\\ v\\,\\ robbins\\ sl\\.\\ robbins\\ pathologic\\ basis\\ of\\ disease\\.\\ 4th\\ ed\\.\\ philadelphia\\,\\ pa\\:\\ wb\\ saunders\\ co\\;\\ 1989\\:777\\.\ \(0\)\
\-\ 7\\)\\ higgins\\ cb\\.\\ essentials\\ of\\ cardiac\\ radiology\\ and\\ imaging\\.\\ philadelphia\\,\\ pa\\:\\ jb\\ lippincott\\ co\\;\\ 1992\\:283\\-331\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ renal\\:\\ 0\\.03538633988533327\ \(0\)\
\-\ rib\\:\\ 0\\.029441051129608306\ \(0\)\
\-\ rcc\\:\\ 0\\.026512998405404633\ \(0\)\
\-\ 10th\\:\\ 0\\.024569767041225606\ \(0\)\
\-\ \\:\\:\\ 0\\.02077074700135985\ \(0\)\
\-\ philadelphia\\:\\ 0\\.0183390763140557\ \(0\)\
\-\ \\%\\:\\ 0\\.018315354058309412\ \(0\)\
\-\ local\\:\\ 0\\.01803293704017494\ \(0\)\
\-\ \\)\\:\\ 0\\.015844251968825305\ \(0\)\
\-\ confined\\:\\ 0\\.015779346945901537\ \(0\)\
\-\ invasion\\:\\ 0\\.015754357037419914\ \(0\)\
\-\ distant\\:\\ 0\\.01527374281003799\ \(0\)\
\-\ carcinoma\\:\\ 0\\.014835697825518326\ \(0\)\
\-\ lytic\\:\\ 0\\.014644279621698935\ \(0\)\
\-\ \\,\\:\\ 0\\.013887882381055325\ \(0\)\
\-\ ed\\:\\ 0\\.013826614612900853\ \(0\)\
\-\ rccs\\:\\ 0\\.013500028214343795\ \(0\)\
\-\ adrenal\\:\\ 0\\.013252318695970471\ \(0\)\
\-\ 3rd\\:\\ 0\\.0129572770146889\ \(0\)\
\-\ 1\\:\\ 0\\.012455291687348893\ \(0\)\
\-\ cell\\:\\ 0\\.01237188742807841\ \(0\)\
\-\ node\\:\\ 0\\.011976243937298833\ \(0\)\
\-\ tnm\\:\\ 0\\.011817620421590182\ \(0\)\
\-\ robson\\:\\ 0\\.011817620421590182\ \(0\)\
\-\ stage\\:\\ 0\\.011163964560270587\ \(0\)\
\-\ robbins\\:\\ 0\\.011035345346910258\ \(0\)\
\-\ or\\:\\ 0\\.010736078472811566\ \(0\)\
\-\ tumor\\:\\ 0\\.010678121065295313\ \(0\)\
\-\ capsule\\:\\ 0\\.010626026834471836\ \(0\)\
\-\ lymph\\:\\ 0\\.010565214116216377\ \(0\)\
\-\ survival\\:\\ 0\\.010523917119531177\ \(0\)\
\-\ photopenia\\:\\ 0\\.010520073927888491\ \(0\)\
\-\ ivc\\:\\ 0\\.010458281501359534\ \(0\)\
\-\ gerota\\:\\ 0\\.010135212628836567\ \(0\)\
\-\ co\\:\\ 0\\.010135212628836567\ \(0\)\
\-\ metastasis\\:\\ 0\\.00979708216324633\ \(0\)\
\-\ 2nd\\:\\ 0\\.009789375648620117\ \(0\)\
\-\ bone\\:\\ 0\\.009755442640703844\ \(0\)\
\-\ disease\\:\\ 0\\.009625296991532417\ \(0\)\
\-\ 5\\-year\\:\\ 0\\.009572081265704382\ \(0\)\
\-\ cystic\\:\\ 0\\.009435806689325262\ \(0\)\
\-\ s\\:\\ 0\\.00938272460610485\ \(0\)\
\-\ guidelines\\:\\ 0\\.009161263522067814\ \(0\)\
\-\ involves\\:\\ 0\\.00912250690086043\ \(0\)\
\-\ fascia\\:\\ 0\\.008698352539107732\ \(0\)\
\-\ pathologic\\:\\ 0\\.008591909514699857\ \(0\)\
\-\ 2\\:\\ 0\\.008453772572023949\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.008399004947298021\ \(0\)\
\-\ microscopic\\:\\ 0\\.008343373038254248\ \(0\)\
\-\ al\\:\\ 0\\.008321351239838334\ \(0\)\
\-\ perinephric\\:\\ 0\\.008291456420067907\ \(0\)\
\-\ regional\\:\\ 0\\.008291456420067907\ \(0\)\
\-\ lippincott\\:\\ 0\\.008241242296296098\ \(0\)\
\-\ metastatic\\:\\ 0\\.008235487762695599\ \(0\)\
\-\ pa\\:\\ 0\\.008209275824441477\ \(0\)\
\-\ saunders\\:\\ 0\\.008192622543900109\ \(0\)\
\-\ et\\:\\ 0\\.00803384019170509\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.007822440243937079\ \(0\)\
\-\ cysts\\:\\ 0\\.007689414125952605\ \(0\)\
\-\ imaging\\:\\ 0\\.007664907444317009\ \(0\)\
\-\ staging\\:\\ 0\\.0075401196414331875\ \(0\)\
\-\ ipsilateral\\:\\ 0\\.0075401196414331875\ \(0\)\
\-\ 7\\:\\ 0\\.007521259292820993\ \(0\)\
\-\ nephrectomy\\:\\ 0\\.007419948714263977\ \(0\)\
\-\ include\\:\\ 0\\.0073419708668615215\ \(0\)\
\-\ 1997\\:\\ 0\\.00733563052562228\ \(0\)\
\-\ scan\\:\\ 0\\.007327018255537453\ \(0\)\
\-\ involvement\\:\\ 0\\.0071943460718862555\ \(0\)\
\-\ \\(\\:\\ 0\\.007190430659395242\ \(0\)\
\-\ criteria\\:\\ 0\\.007155258342381265\ \(0\)\
\-\ vein\\:\\ 0\\.0071024502037077735\ \(0\)\
\-\ \\-\\:\\ 0\\.007012742950644578\ \(0\)\
\-\ lesions\\:\\ 0\\.0070063108923244955\ \(0\)\
\-\ exclude\\:\\ 0\\.006950769226570357\ \(0\)\
\-\ concerning\\:\\ 0\\.006867971031669476\ \(0\)\
\-\ to\\:\\ 0\\.006867098221518156\ \(0\)\
\-\ thickness\\:\\ 0\\.0067516067024536676\ \(0\)\
\-\ 142\\/89\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ anxious\\-appearing\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ cryoprotective\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ a\\-interferon\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ anti\\-angiogenic\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ 90\\-100\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ thorax\\/abdomen\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ metastasis\\-\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ children\\-\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ hematochezia\\/melena\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ dose\\-dependent\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ cadmium\\/benzene\\/asbestos\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ phenacetin\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ predispositions\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ vein\\/ivc\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ one\\/two\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ thin\\/fine\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ thick\\/\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ non\\-uniform\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ thieme\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ pollack\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ ralph\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ rugo\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ sheth\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ sheila\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ multidector\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ ct\\.\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ s237\\-\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ s254\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ 1989\\:777\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ 1992\\:283\\-331\\:\\ 0\\.006750014107171898\ \(0\)\
\-\ collecting\\:\\ 0\\.006678669414568132\ \(0\)\
\-\ masses\\:\\ 0\\.006635357728934351\ \(0\)\
\-\ extend\\:\\ 0\\.006558834503542484\ \(0\)\
\-\ often\\:\\ 0\\.006262956083888942\ \(0\)\
\-\ into\\:\\ 0\\.006227645843674447\ \(0\)\
\-\ il\\-2\\:\\ 0\\.0062192735401275295\ \(0\)\
\-\ antero\\-lateral\\:\\ 0\\.0062192735401275295\ \(0\)\
\-\ multi\\-centric\\:\\ 0\\.0062192735401275295\ \(0\)\
\-\ subdivided\\:\\ 0\\.0062192735401275295\ \(0\)\
\-\ t3a\\:\\ 0\\.0062192735401275295\ \(0\)\
\-\ t3b\\:\\ 0\\.0062192735401275295\ \(0\)\
\-\ t3c\\:\\ 0\\.0062192735401275295\ \(0\)\
\-\ martin\\:\\ 0\\.0062192735401275295\ \(0\)\
\-\ tierney\\:\\ 0\\.0062192735401275295\ \(0\)\
\-\ hematuria\\:\\ 0\\.006207265680197155\ \(0\)\
\-\ direct\\:\\ 0\\.00618130923561251\ \(0\)\
\-\ current\\:\\ 0\\.006130680043788791\ \(0\)\
\-\ ca\\:\\ 0\\.006093777208292527\ \(0\)\
\-\ pole\\:\\ 0\\.006093777208292527\ \(0\)\
\-\ duct\\:\\ 0\\.0059995078468845124\ \(0\)\
\-\ can\\:\\ 0\\.005936362488419816\ \(0\)\
\-\ nodes\\:\\ 0\\.0059107065334842845\ \(0\)\
\-\ immunotherapy\\:\\ 0\\.005908810210795091\ \(0\)\
\-\ vacation\\:\\ 0\\.005908810210795091\ \(0\)\
\-\ mexico\\:\\ 0\\.005908810210795091\ \(0\)\
\-\ iiic\\:\\ 0\\.005908810210795091\ \(0\)\
\-\ bosniak\\:\\ 0\\.005908810210795091\ \(0\)\
\-\ iif\\:\\ 0\\.005908810210795091\ \(0\)\
\-\ howard\\:\\ 0\\.005908810210795091\ \(0\)\
\-\ mcphee\\:\\ 0\\.005908810210795091\ \(0\)\
\-\ papadakis\\:\\ 0\\.005908810210795091\ \(0\)\
\-\ cotran\\:\\ 0\\.005908810210795091\ \(0\)\
\-\ higgins\\:\\ 0\\.005908810210795091\ \(0\)\
\-\ cb\\:\\ 0\\.005908810210795091\ \(0\)\
\-\ 8\\.2\\:\\ 0\\.0056885329730831605\ \(0\)\
\-\ five\\-year\\:\\ 0\\.0056885329730831605\ \(0\)\
\-\ infradiaphragmatic\\:\\ 0\\.0056885329730831605\ \(0\)\
\-\ three\\-dimensional\\:\\ 0\\.0056885329730831605\ \(0\)\
\-\ kumar\\:\\ 0\\.0056885329730831605\ \(0\)\
\-\ wall\\:\\ 0\\.005685664135311056\ \(0\)\
\-\ have\\:\\ 0\\.005667497942925243\ \(0\)\
\-\ ii\\:\\ 0\\.005644134317064969\ \(0\)\
\-\ metastases\\:\\ 0\\.0055907081930214155\ \(0\)\
\-\ but\\:\\ 0\\.005581939666258921\ \(0\)\
\-\ gland\\:\\ 0\\.005573305806114348\ \(0\)\
\-\ radiology\\:\\ 0\\.005530645845160342\ \(0\)\
\-\ denies\\:\\ 0\\.005522254626531512\ \(0\)\
\-\ 14\\.5\\:\\ 0\\.005517672673455129\ \(0\)\
\-\ 50\\-70\\:\\ 0\\.005517672673455129\ \(0\)\
\-\ iiia\\:\\ 0\\.005517672673455129\ \(0\)\
\-\ iva\\:\\ 0\\.005517672673455129\ \(0\)\
\-\ ivb\\:\\ 0\\.005517672673455129\ \(0\)\
\-\ purely\\:\\ 0\\.005517672673455129\ \(0\)\
\-\ weissleder\\:\\ 0\\.005517672673455129\ \(0\)\
\-\ lm\\:\\ 0\\.005517672673455129\ \(0\)\
\-\ rs\\:\\ 0\\.005517672673455129\ \(0\)\
\-\ secondary\\:\\ 0\\.005487817687233096\ \(0\)\
\-\ 4\\:\\ 0\\.005469307592294898\ \(0\)\
\-\ i\\:\\ 0\\.00540936400494412\ \(0\)\
\-\ unresectable\\:\\ 0\\.005378069643750722\ \(0\)\
\-\ homogeneity\\:\\ 0\\.005378069643750722\ \(0\)\
\-\ primer\\:\\ 0\\.005378069643750722\ \(0\)\
\-\ essentials\\:\\ 0\\.005378069643750722\ \(0\)\
\-\ are\\:\\ 0\\.00535164106828301\ \(0\)\
\-\ cyst\\:\\ 0\\.005274971981683237\ \(0\)\
\-\ invaded\\:\\ 0\\.005260036963944246\ \(0\)\
\-\ prostheses\\:\\ 0\\.005260036963944246\ \(0\)\
\-\ sl\\:\\ 0\\.005260036963944246\ \(0\)\
\-\ solid\\:\\ 0\\.005219520141663675\ \(0\)\
\-\ diagnostic\\:\\ 0\\.005185563238915861\ \(0\)\
\-\ drops\\:\\ 0\\.0051577924060387925\ \(0\)\
\-\ artifacts\\:\\ 0\\.0051577924060387925\ \(0\)\
\-\ iiib\\:\\ 0\\.0051577924060387925\ \(0\)\
\-\ hope\\:\\ 0\\.0051577924060387925\ \(0\)\
\-\ sj\\:\\ 0\\.0051577924060387925\ \(0\)\
\-\ jb\\:\\ 0\\.0051577924060387925\ \(0\)\
\-\ vs\\:\\ 0\\.005152342986831237\ \(0\)\
\-\ s1\\/s2\\:\\ 0\\.005067606314418284\ \(0\)\
\-\ infrequent\\:\\ 0\\.005067606314418284\ \(0\)\
\-\ urography\\:\\ 0\\.005067606314418284\ \(0\)\
\-\ \\<\\:\\ 0\\.00505063633614363\ \(0\)\
\-\ structures\\:\\ 0\\.005038385122258369\ \(0\)\
\-\ hematemesis\\:\\ 0\\.00498693210641076\ \(0\)\
\-\ wb\\:\\ 0\\.00498693210641076\ \(0\)\
\-\ cardiac\\:\\ 0\\.004984436130093369\ \(0\)\
\-\ 50\\:\\ 0\\.004978557452747021\ \(0\)\
\-\ lungs\\:\\ 0\\.004955265846830438\ \(0\)\
\-\ tumors\\:\\ 0\\.0049153389857128655\ \(0\)\
\-\ cure\\:\\ 0\\.004913953408245121\ \(0\)\
\-\ reproducible\\:\\ 0\\.004913953408245121\ \(0\)\
\-\ diaphoresis\\:\\ 0\\.004913953408245121\ \(0\)\
\-\ valuable\\:\\ 0\\.004913953408245121\ \(0\)\
\-\ concepts\\:\\ 0\\.004913953408245121\ \(0\)\
\-\ more\\:\\ 0\\.004909287081115237\ \(0\)\
\-\ calcifications\\:\\ 0\\.004865488138794415\ \(0\)\
\-\ responses\\:\\ 0\\.004847329076706354\ \(0\)\
\-\ attenuating\\:\\ 0\\.004847329076706354\ \(0\)\
\-\ precise\\:\\ 0\\.004847329076706354\ \(0\)\
\-\ chapter\\:\\ 0\\.004847329076706354\ \(0\)\
\-\ in\\:\\ 0\\.00483993755903815\ \(0\)\
\-\ clear\\:\\ 0\\.004838478733762091\ \(0\)\
\-\ right\\:\\ 0\\.00483263550059182\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.004811937452978569\ \(0\)\
\-\ diagnosed\\:\\ 0\\.004811937452978569\ \(0\)\
\-\ technetium\\:\\ 0\\.004786040632852191\ \(0\)\
\-\ iv\\:\\ 0\\.004775535891977173\ \(0\)\
\-\ bilateral\\:\\ 0\\.004763746698272077\ \(0\)\
\-\ luq\\:\\ 0\\.004729296396899878\ \(0\)\
\-\ heterogeneity\\:\\ 0\\.004729296396899878\ \(0\)\
\-\ paraneoplastic\\:\\ 0\\.004729296396899878\ \(0\)\
\-\ brant\\:\\ 0\\.004729296396899878\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.004690575474947727\ \(0\)\
\-\ weight\\:\\ 0\\.004690575474947727\ \(0\)\
\-\ w\\.b\\:\\ 0\\.004676468777078321\ \(0\)\
\-\ company\\:\\ 0\\.004676468777078321\ \(0\)\
\-\ noted\\:\\ 0\\.004652575471177475\ \(0\)\
\-\ \\;\\:\\ 0\\.004652575471177475\ \(0\)\
\-\ multilocular\\:\\ 0\\.0046270518389944235\ \(0\)\
\-\ photopenic\\:\\ 0\\.0046270518389944235\ \(0\)\
\-\ 99m\\:\\ 0\\.0046270518389944235\ \(0\)\
\-\ kidney\\:\\ 0\\.00461008186071977\ \(0\)\
\-\ 97\\:\\ 0\\.004580631761033907\ \(0\)\
\-\ indeterminate\\:\\ 0\\.004580631761033907\ \(0\)\
\-\ resnick\\:\\ 0\\.004580631761033907\ \(0\)\
\-\ ct\\:\\ 0\\.004576200816968005\ \(0\)\
\-\ and\\:\\ 0\\.004548466454183162\ \(0\)\
\-\ granular\\:\\ 0\\.0045368657473739155\ \(0\)\
\-\ septa\\:\\ 0\\.0045368657473739155\ \(0\)\
\-\ helms\\:\\ 0\\.0045368657473739155\ \(0\)\
\-\ benign\\:\\ 0\\.004516156764216235\ \(0\)\
\-\ diagnosis\\:\\ 0\\.00450739509367631\ \(0\)\
\-\ ranging\\:\\ 0\\.004495466649923475\ \(0\)\
\-\ 91\\:\\ 0\\.004495466649923475\ \(0\)\
\-\ mdp\\:\\ 0\\.004495466649923475\ \(0\)\
\-\ ma\\:\\ 0\\.004495466649923475\ \(0\)\
\-\ 10\\-15\\:\\ 0\\.004456191539366392\ \(0\)\
\-\ hippel\\-lindau\\:\\ 0\\.004456191539366392\ \(0\)\
\-\ jr\\:\\ 0\\.004456191539366392\ \(0\)\
\-\ fever\\:\\ 0\\.004427660990125522\ \(0\)\
\-\ resistant\\:\\ 0\\.004418833067567439\ \(0\)\
\-\ subtypes\\:\\ 0\\.004418833067567439\ \(0\)\
\-\ left\\:\\ 0\\.004392520379508031\ \(0\)\
\-\ hypercalcemia\\:\\ 0\\.004383212841200752\ \(0\)\
\-\ accuracy\\:\\ 0\\.004383212841200752\ \(0\)\
\-\ genitourinary\\:\\ 0\\.004383212841200752\ \(0\)\
\-\ vol\\:\\ 0\\.004383212841200752\ \(0\)\
\-\ fundamentals\\:\\ 0\\.004383212841200752\ \(0\)\
\-\ x\\:\\ 0\\.004317100054130899\ \(0\)\
\-\ notes\\:\\ 0\\.004316588509661985\ \(0\)\
\-\ w\\:\\ 0\\.004316588509661985\ \(0\)\
\-\ radiation\\:\\ 0\\.004294412327047989\ \(0\)\
\-\ pharyngeal\\:\\ 0\\.004285331239738359\ \(0\)\
\-\ 1\\.9\\:\\ 0\\.004285331239738359\ \(0\)\
\-\ dx\\:\\ 0\\.004285331239738359\ \(0\)\
\-\ yr\\:\\ 0\\.004285331239738359\ \(0\)\
\-\ epithelium\\:\\ 0\\.004285331239738359\ \(0\)\
\-\ oncocytoma\\:\\ 0\\.004255300065807822\ \(0\)\
\-\ lateral\\:\\ 0\\.004241963351358079\ \(0\)\
\-\ groups\\:\\ 0\\.004198555829855509\ \(0\)\
\-\ malignancies\\:\\ 0\\.004171686519127124\ \(0\)\
\-\ contained\\:\\ 0\\.004171686519127124\ \(0\)\
\-\ oncology\\:\\ 0\\.004171686519127124\ \(0\)\
\-\ utilized\\:\\ 0\\.004145728210033953\ \(0\)\
\-\ hispanic\\:\\ 0\\.004145728210033953\ \(0\)\
\-\ definition\\:\\ 0\\.004145728210033953\ \(0\)\
\-\ bs\\:\\ 0\\.004120621148148049\ \(0\)\
\-\ accompanying\\:\\ 0\\.004120621148148049\ \(0\)\
\-\ accounts\\:\\ 0\\.004120621148148049\ \(0\)\
\-\ von\\:\\ 0\\.004120621148148049\ \(0\)\
\-\ nodularity\\:\\ 0\\.004120621148148049\ \(0\)\
\-\ enhancing\\:\\ 0\\.004104063603192587\ \(0\)\
\-\ radical\\:\\ 0\\.0040963112719500545\ \(0\)\
\-\ dialysis\\:\\ 0\\.0040963112719500545\ \(0\)\
\-\ likelihood\\:\\ 0\\.004072749511868314\ \(0\)\
\-\ f\\/u\\:\\ 0\\.004072749511868314\ \(0\)\
\-\ 82\\:\\ 0\\.004049891193989538\ \(0\)\
\-\ tx\\:\\ 0\\.004049891193989538\ \(0\)\
\-\ interface\\:\\ 0\\.004049891193989538\ \(0\)\
\-\ eomi\\:\\ 0\\.004027695530227477\ \(0\)\
\-\ ext\\:\\ 0\\.0040061251803295474\ \(0\)\
\-\ transitional\\:\\ 0\\.0040061251803295474\ \(0\)\
\-\ familial\\:\\ 0\\.0040061251803295474\ \(0\)\
\-\ septations\\:\\ 0\\.0040061251803295474\ \(0\)\
\-\ wilkins\\:\\ 0\\.0040061251803295474\ \(0\)\
\-\ infected\\:\\ 0\\.003985145873906795\ \(0\)\
\-\ ingestion\\:\\ 0\\.003985145873906795\ \(0\)\
\-\ exophytic\\:\\ 0\\.003985145873906795\ \(0\)\
\-\ tenderness\\:\\ 0\\.003979957615438948\ \(0\)\
\-\ fat\\:\\ 0\\.003979957615438948\ \(0\)\
\-\ excessive\\:\\ 0\\.003964726082879106\ \(0\)\
\-\ angiomyolipoma\\:\\ 0\\.003944836736475384\ \(0\)\
\-\ cold\\:\\ 0\\.003944836736475384\ \(0\)\
\-\ cr\\:\\ 0\\.003925450972322023\ \(0\)\
\-\ destructive\\:\\ 0\\.003925450972322023\ \(0\)\
\-\ documented\\:\\ 0\\.003925450972322023\ \(0\)\
\-\ accomplished\\:\\ 0\\.003925450972322023\ \(0\)\
\-\ basis\\:\\ 0\\.003925450972322023\ \(0\)\
\-\ gallops\\:\\ 0\\.003906543918271202\ \(0\)\
\-\ distortion\\:\\ 0\\.00388809250052307\ \(0\)\
\-\ glands\\:\\ 0\\.00388809250052307\ \(0\)\
\-\ primary\\:\\ 0\\.0038765455787070392\ \(0\)\
\-\ variety\\:\\ 0\\.0038700752743284347\ \(0\)\
\-\ role\\:\\ 0\\.0038700752743284347\ \(0\)\
\-\ mosby\\:\\ 0\\.003852472274156384\ \(0\)\
\-\ williams\\:\\ 0\\.003852472274156384\ \(0\)\
\-\ organ\\:\\ 0\\.0038352648807015153\ \(0\)\
\-\ m\\.\\:\\ 0\\.0038352648807015153\ \(0\)\
\-\ radiographics\\:\\ 0\\.0038352648807015153\ \(0\)\
\-\ ultimately\\:\\ 0\\.0038184357025094974\ \(0\)\
\-\ scintigraphy\\:\\ 0\\.0038019684703341806\ \(0\)\
\-\ myeloma\\:\\ 0\\.0038019684703341806\ \(0\)\
\-\ beyond\\:\\ 0\\.0038019684703341806\ \(0\)\
\-\ evaluation\\:\\ 0\\.003801284526534162\ \(0\)\
\-\ loss\\:\\ 0\\.0037985668797372737\ \(0\)\
\-\ 2000\\:\\ 0\\.003785847942617617\ \(0\)\
\-\ 2008\\:\\ 0\\.003785847942617617\ \(0\)\
\-\ mets\\:\\ 0\\.0037700598207165937\ \(0\)\
\-\ o2\\:\\ 0\\.0037545906726939907\ \(0\)\
\-\ rubs\\:\\ 0\\.0037545906726939907\ \(0\)\
\-\ hereditary\\:\\ 0\\.0037545906726939907\ \(0\)\
\-\ organs\\:\\ 0\\.0037545906726939907\ \(0\)\
\-\ when\\:\\ 0\\.003747827316410422\ \(0\)\
\-\ po\\:\\ 0\\.0037394278646571\ \(0\)\
\-\ syndromes\\:\\ 0\\.0037394278646571\ \(0\)\
\-\ robert\\:\\ 0\\.0037394278646571\ \(0\)\
\-\ sat\\:\\ 0\\.003724559498763454\ \(0\)\
\-\ sweats\\:\\ 0\\.003724559498763454\ \(0\)\
\-\ ttp\\:\\ 0\\.0037099743571319885\ \(0\)\
\-\ hormone\\:\\ 0\\.0037099743571319885\ \(0\)\
\-\ water\\:\\ 0\\.0037099743571319885\ \(0\)\
\-\ 1999\\:\\ 0\\.0037099743571319885\ \(0\)\
\-\ all\\:\\ 0\\.003701261086418516\ \(0\)\
\-\ w\\/o\\:\\ 0\\.0036956618509971085\ \(0\)\
\-\ 85\\:\\ 0\\.003654262753546668\ \(0\)\
\-\ mass\\:\\ 0\\.0036400030840660477\ \(0\)\
\-\ bun\\:\\ 0\\.0036149876429895852\ \(0\)\
\-\ requiring\\:\\ 0\\.0036149876429895852\ \(0\)\
\-\ gen\\:\\ 0\\.0036023312096425627\ \(0\)\
\-\ tuberous\\:\\ 0\\.0036023312096425627\ \(0\)\
\-\ modality\\:\\ 0\\.0035898805811036805\ \(0\)\
\-\ v\\:\\ 0\\.0035898805811036805\ \(0\)\
\-\ ra\\:\\ 0\\.0035776291711906326\ \(0\)\
\-\ genetic\\:\\ 0\\.0035776291711906326\ \(0\)\
\-\ been\\:\\ 0\\.003560175940986204\ \(0\)\
\-\ consider\\:\\ 0\\.0035536991991354217\ \(0\)\
\-\ male\\:\\ 0\\.0035494767332790353\ \(0\)\
\-\ one\\:\\ 0\\.0035462961459581076\ \(0\)\
\-\ sharp\\:\\ 0\\.0035420089448239453\ \(0\)\
\-\ murmurs\\:\\ 0\\.00351915062694517\ \(0\)\
\-\ spleen\\:\\ 0\\.00351915062694517\ \(0\)\
\-\ cm\\:\\ 0\\.0035098868573001317\ \(0\)\
\-\ therapy\\:\\ 0\\.003498684220889147\ \(0\)\
\-\ due\\:\\ 0\\.003492001765624563\ \(0\)\
\-\ 2001\\:\\ 0\\.0034753846132851785\ \(0\)\
\-\ abd\\:\\ 0\\.003464823110886759\ \(0\)\
\-\ vena\\:\\ 0\\.003464823110886759\ \(0\)\
\-\ mild\\:\\ 0\\.0034460236660507457\ \(0\)\
\-\ cava\\:\\ 0\\.003444127343361553\ \(0\)\
\-\ we\\:\\ 0\\.003444127343361553\ \(0\)\
\-\ thick\\:\\ 0\\.003433985515834738\ \(0\)\
\-\ than\\:\\ 0\\.003428865015188781\ \(0\)\
\-\ common\\:\\ 0\\.0034246052250480816\ \(0\)\
\-\ rebound\\:\\ 0\\.003423976265017469\ \(0\)\
\-\ cta\\:\\ 0\\.003414096169431016\ \(0\)\
\-\ exposure\\:\\ 0\\.0034043419383610082\ \(0\)\
\-\ minimally\\:\\ 0\\.0034043419383610082\ \(0\)\
\-\ complicated\\:\\ 0\\.0033947104052776543\ \(0\)\
\-\ patients\\:\\ 0\\.003386791116946441\ \(0\)\
\-\ \\+\\:\\ 0\\.0033758033512268338\ \(0\)\
\-\ well\\-defined\\:\\ 0\\.003366522064448622\ \(0\)\
\-\ 75\\:\\ 0\\.0033482903273171377\ \(0\)\
\-\ pancreas\\:\\ 0\\.0033482903273171377\ \(0\)\
\-\ rr\\:\\ 0\\.003339334707284066\ \(0\)\
\-\ rrr\\:\\ 0\\.003339334707284066\ \(0\)\
\-\ adults\\:\\ 0\\.003339334707284066\ \(0\)\
\-\ confirm\\:\\ 0\\.0033304826227503175\ \(0\)\
\-\ on\\:\\ 0\\.003325686121127541\ \(0\)\
\-\ papillary\\:\\ 0\\.003321731707112015\ \(0\)\
\-\ return\\:\\ 0\\.003313079673992618\ \(0\)\
\-\ smoking\\:\\ 0\\.003304524313657147\ \(0\)\
\-\ anatomic\\:\\ 0\\.003304524313657147\ \(0\)\
\-\ thrombus\\:\\ 0\\.003304524313657147\ \(0\)\
\-\ combination\\:\\ 0\\.00329606348962454\ \(0\)\
\-\ older\\:\\ 0\\.00329606348962454\ \(0\)\
\-\ 4th\\:\\ 0\\.00329606348962454\ \(0\)\
\-\ no\\:\\ 0\\.0032941965953438056\ \(0\)\
\-\ discomfort\\:\\ 0\\.003279417251771242\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.003271227903289812\ \(0\)\
\-\ chills\\:\\ 0\\.003271227903289812\ \(0\)\
\-\ hyperdense\\:\\ 0\\.003271227903289812\ \(0\)\
\-\ need\\:\\ 0\\.0032631252162067057\ \(0\)\
\-\ unilateral\\:\\ 0\\.0032471726228660916\ \(0\)\
\-\ extent\\:\\ 0\\.0032471726228660916\ \(0\)\
\-\ hx\\:\\ 0\\.003239319253672225\ \(0\)\
\-\ arise\\:\\ 0\\.003239319253672225\ \(0\)\
\-\ skeletal\\:\\ 0\\.0032315456154915073\ \(0\)\
\-\ simple\\:\\ 0\\.003223850105649622\ \(0\)\
\-\ erythema\\:\\ 0\\.003216231169314884\ \(0\)\
\-\ consistent\\:\\ 0\\.0032087262922376775\ \(0\)\
\-\ expansile\\:\\ 0\\.0032086872976127313\ \(0\)\
\-\ components\\:\\ 0\\.0032086872976127313\ \(0\)\
\-\ increased\\:\\ 0\\.0032013549491572064\ \(0\)\
\-\ poorly\\:\\ 0\\.0031938189317190857\ \(0\)\
\-\ hr\\:\\ 0\\.0031864916338506704\ \(0\)\
\-\ options\\:\\ 0\\.00317923379008762\ \(0\)\
\-\ night\\:\\ 0\\.00317923379008762\ \(0\)\
\-\ smaller\\:\\ 0\\.0031720440960984623\ \(0\)\
\-\ contour\\:\\ 0\\.0031720440960984623\ \(0\)\
\-\ heent\\:\\ 0\\.00316492128395274\ \(0\)\
\-\ spread\\:\\ 0\\.00316492128395274\ \(0\)\
\-\ larger\\:\\ 0\\.003150871407483983\ \(0\)\
\-\ 70\\:\\ 0\\.0031439419775299883\ \(0\)\
\-\ completely\\:\\ 0\\.0031439419775299883\ \(0\)\
\-\ vitals\\:\\ 0\\.0031302684573155876\ \(0\)\
\-\ still\\:\\ 0\\.0031168348358370968\ \(0\)\
\-\ gross\\:\\ 0\\.0031168348358370968\ \(0\)\
\-\ shift\\:\\ 0\\.0031036328400985773\ \(0\)\
\-\ nature\\:\\ 0\\.003097116232389612\ \(0\)\
\-\ involve\\:\\ 0\\.0030842470759452163\ \(0\)\
\-\ flank\\:\\ 0\\.003077892709318344\ \(0\)\
\-\ iii\\:\\ 0\\.003071590642598194\ \(0\)\
\-\ 3\\:\\ 0\\.003064281051617978\ \(0\)\
\-\ hemorrhagic\\:\\ 0\\.0030529898060215905\ \(0\)\
\-\ embolization\\:\\ 0\\.0030468886041462636\ \(0\)\
\-\ tubular\\:\\ 0\\.0030468886041462636\ \(0\)\
\-\ be\\:\\ 0\\.0030270062557670656\ \(0\)\
\-\ afebrile\\:\\ 0\\.0030229586320910536\ \(0\)\
\-\ unable\\:\\ 0\\.0030229586320910536\ \(0\)\
\-\ most\\:\\ 0\\.003021187047056778\ \(0\)\
\-\ posterior\\:\\ 0\\.003016291805057349\ \(0\)\
\-\ is\\:\\ 0\\.0030138096850636136\ \(0\)\
\-\ 35\\:\\ 0\\.003011268377779577\ \(0\)\
\-\ kidneys\\:\\ 0\\.003011268377779577\ \(0\)\
\-\ subtle\\:\\ 0\\.003005489506695823\ \(0\)\
\-\ regions\\:\\ 0\\.0029940609843247083\ \(0\)\
\-\ as\\:\\ 0\\.0029691673182866644\ \(0\)\
\-\ incidentally\\:\\ 0\\.00296621439613874\ \(0\)\
\-\ the\\:\\ 0\\.00296399691554481\ \(0\)\
\-\ 21\\:\\ 0\\.0029607645739573737\ \(0\)\
\-\ pe\\:\\ 0\\.0029393450854103553\ \(0\)\
\-\ factors\\:\\ 0\\.0029393450854103553\ \(0\)\
\-\ from\\:\\ 0\\.0029091172583940563\ \(0\)\
\-\ infarct\\:\\ 0\\.002903244948790369\ \(0\)\
\-\ represent\\:\\ 0\\.0028736013713166397\ \(0\)\
\-\ resulting\\:\\ 0\\.0028736013713166397\ \(0\)\
\-\ arterial\\:\\ 0\\.002863969838233286\ \(0\)\
\-\ either\\:\\ 0\\.0028497459595403798\ \(0\)\
\-\ bp\\:\\ 0\\.002840408078151545\ \(0\)\
\-\ thrombosis\\:\\ 0\\.0028085941402396977\ \(0\)\
\-\ good\\:\\ 0\\.002799742055705949\ \(0\)\
\-\ cortex\\:\\ 0\\.002799742055705949\ \(0\)\
\-\ for\\:\\ 0\\.002791378823287577\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.0027823391069482493\ \(0\)\
\-\ site\\:\\ 0\\.002765322922580171\ \(0\)\
\-\ multiple\\:\\ 0\\.002756211337640534\ \(0\)\
\-\ best\\:\\ 0\\.0027528044401900257\ \(0\)\
\-\ surgical\\:\\ 0\\.0027507224659287194\ \(0\)\
\-\ s\\/p\\:\\ 0\\.0027445710621071297\ \(0\)\
\-\ references\\:\\ 0\\.0027203891539522304\ \(0\)\
\-\ nodules\\:\\ 0\\.002712495302758615\ \(0\)\
\-\ located\\:\\ 0\\.002693109538605254\ \(0\)\
\-\ thin\\:\\ 0\\.002689290594109818\ \(0\)\
\-\ occurs\\:\\ 0\\.0026854906022705156\ \(0\)\
\-\ thyroid\\:\\ 0\\.002681709375899472\ \(0\)\
\-\ of\\:\\ 0\\.0026761975681008064\ \(0\)\
\-\ presents\\:\\ 0\\.002673268446413363\ \(0\)\
\-\ lesion\\:\\ 0\\.002665475078101768\ \(0\)\
\-\ visualized\\:\\ 0\\.002648493223043251\ \(0\)\
\-\ 25\\:\\ 0\\.0026448899374097038\ \(0\)\
\-\ results\\:\\ 0\\.002641303529054094\ \(0\)\
\-\ considered\\:\\ 0\\.002641303529054094\ \(0\)\
\-\ nausea\\:\\ 0\\.0026341807169083715\ \(0\)\
\-\ attenuation\\:\\ 0\\.002630644004920397\ \(0\)\
\-\ cells\\:\\ 0\\.002623619214509952\ \(0\)\
\-\ partial\\:\\ 0\\.0026166582867142\ \(0\)\
\-\ 15\\:\\ 0\\.0026097600708318374\ \(0\)\
\-\ irregular\\:\\ 0\\.0026097600708318374\ \(0\)\
\-\ necrosis\\:\\ 0\\.002582772368640662\ \(0\)\
\-\ hypertension\\:\\ 0\\.0025794648179940185\ \(0\)\
\-\ system\\:\\ 0\\.0025761714934156186\ \(0\)\
\-\ colon\\:\\ 0\\.0025696270366174115\ \(0\)\
\-\ \\#\\:\\ 0\\.002566375665345244\ \(0\)\
\-\ reveals\\:\\ 0\\.0025599140507618864\ \(0\)\
\-\ rate\\:\\ 0\\.002550322733901871\ \(0\)\
\-\ vomiting\\:\\ 0\\.002498130810907259\ \(0\)\
\-\ within\\:\\ 0\\.0024963727540368787\ \(0\)\
\-\ management\\:\\ 0\\.0024690133563978877\ \(0\)\
\-\ activity\\:\\ 0\\.0024548595932477324\ \(0\)\
\-\ throughout\\:\\ 0\\.0024492705408115825\ \(0\)\
\-\ defect\\:\\ 0\\.0024492705408115825\ \(0\)\
\-\ \\â\\€\\œ\\:\\ 0\\.0024437219891111483\ \(0\)\
\-\ appears\\:\\ 0\\.0024354738290943713\ \(0\)\
\-\ \\â\\€\\\\:\\ 0\\.002430024006913005\ \(0\)\
\-\ abnormality\\:\\ 0\\.0024139034791964414\ \(0\)\
\-\ breast\\:\\ 0\\.0024139034791964414\ \(0\)\
\-\ early\\:\\ 0\\.002392924172773689\ \(0\)\
\-\ wbc\\:\\ 0\\.0023852027952341592\ \(0\)\
\-\ venous\\:\\ 0\\.0023750272729380776\ \(0\)\
\-\ calcification\\:\\ 0\\.0023750272729380776\ \(0\)\
\-\ risk\\:\\ 0\\.0023699897759257935\ \(0\)\
\-\ peripheral\\:\\ 0\\.0023674834012359243\ \(0\)\
\-\ malignant\\:\\ 0\\.0023649852039657744\ \(0\)\
\-\ 20\\:\\ 0\\.0023526150353422788\ \(0\)\
\-\ sclerosis\\:\\ 0\\.0023501648035423777\ \(0\)\
\-\ status\\:\\ 0\\.0023356258202003473\ \(0\)\
\-\ extension\\:\\ 0\\.0023356258202003473\ \(0\)\
\-\ palpable\\:\\ 0\\.0023190053924960112\ \(0\)\
\-\ \\&\\:\\ 0\\.002298153056769856\ \(0\)\
\-\ involving\\:\\ 0\\.0022958707993899646\ \(0\)\
\-\ being\\:\\ 0\\.0022800826774889422\ \(0\)\
\-\ labs\\:\\ 0\\.00227563093946029\ \(0\)\
\-\ liver\\:\\ 0\\.0022559123360128054\ \(0\)\
\-\ three\\:\\ 0\\.0022056847077694566\ \(0\)\
\-\ areas\\:\\ 0\\.0022016440821179687\ \(0\)\
\-\ size\\:\\ 0\\.002193626241484511\ \(0\)\
\-\ palpation\\:\\ 0\\.0021837205821960584\ \(0\)\
\-\ swelling\\:\\ 0\\.0021797939234158748\ \(0\)\
\-\ cases\\:\\ 0\\.0021797939234158748\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.002177838119583488\ \(0\)\
\-\ density\\:\\ 0\\.0021528570879479013\ \(0\)\
\-\ bilaterally\\:\\ 0\\.002149085174980018\ \(0\)\
\-\ superior\\:\\ 0\\.002089390273395246\ \(0\)\
\-\ radiograph\\:\\ 0\\.0020841873307207983\ \(0\)\
\-\ differential\\:\\ 0\\.0020773046166561483\ \(0\)\
\-\ area\\:\\ 0\\.002068787323226851\ \(0\)\
\-\ abscess\\:\\ 0\\.002068787323226851\ \(0\)\
\-\ adjacent\\:\\ 0\\.002068787323226851\ \(0\)\
\-\ resection\\:\\ 0\\.0020405173472589733\ \(0\)\
\-\ clinical\\:\\ 0\\.002013254058243495\ \(0\)\
\-\ medical\\:\\ 0\\.002013254058243495\ \(0\)\
\-\ age\\:\\ 0\\.0019915086719328534\ \(0\)\
\-\ usually\\:\\ 0\\.0019869282188872584\ \(0\)\
\-\ diffuse\\:\\ 0\\.0019808632621556776\ \(0\)\
\-\ only\\:\\ 0\\.001967390243862891\ \(0\)\
\-\ proximal\\:\\ 0\\.0019644281636347744\ \(0\)\
\-\ 6\\:\\ 0\\.0019541502001339008\ \(0\)\
\-\ 5\\:\\ 0\\.0019143647951333565\ \(0\)\
\-\ infection\\:\\ 0\\.0019020035023528386\ \(0\)\
\-\ lung\\:\\ 0\\.0018952213784370186\ \(0\)\
\-\ y\\.o\\:\\ 0\\.001888498799836677\ \(0\)\
\-\ with\\:\\ 0\\.0018813841484591764\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0018699836404207394\ \(0\)\
\-\ focal\\:\\ 0\\.0018686781042407366\ \(0\)\
\-\ likely\\:\\ 0\\.0018455512756015747\ \(0\)\
\-\ chronic\\:\\ 0\\.0018430242212151607\ \(0\)\
\-\ a\\:\\ 0\\.0018220511569001592\ \(0\)\
\-\ however\\:\\ 0\\.00182187446829791\ \(0\)\
\-\ low\\:\\ 0\\.001819424236498009\ \(0\)\
\-\ \\.\\:\\ 0\\.0017940041213054014\ \(0\)\
\-\ enhancement\\:\\ 0\\.0017538198821769036\ \(0\)\
\-\ these\\:\\ 0\\.0017027907289110568\ \(0\)\
\-\ prior\\:\\ 0\\.0016800250935699568\ \(0\)\
\-\ both\\:\\ 0\\.0016709035150736\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.0016080666444347757\ \(0\)\
\-\ pain\\:\\ 0\\.0015981748354222584\ \(0\)\
\-\ soft\\:\\ 0\\.0015933589310823508\ \(0\)\
\-\ upper\\:\\ 0\\.0015789284114614995\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.0015771435696648108\ \(0\)\
\-\ chest\\:\\ 0\\.0015656424196458796\ \(0\)\
\-\ tissue\\:\\ 0\\.0015508584903924914\ \(0\)\
\-\ associated\\:\\ 0\\.0015439988988573522\ \(0\)\
\-\ without\\:\\ 0\\.001540592010993997\ \(0\)\
\-\ other\\:\\ 0\\.0015081459025286744\ \(0\)\
\-\ contrast\\:\\ 0\\.0014646061920428066\ \(0\)\
\-\ large\\:\\ 0\\.0014307369309579478\ \(0\)\
\-\ findings\\:\\ 0\\.0013926775924884838\ \(0\)\
\-\ treatment\\:\\ 0\\.0013243621436453959\ \(0\)\
\-\ has\\:\\ 0\\.00122871360681032\ \(0\)\
\-\ normal\\:\\ 0\\.0010257369483913485\ \(0\)\
\-\ not\\:\\ 0\\.0009454966858667193\ \(0\)\
\-\ history\\:\\ 0\\.0009036864760391144\ \(0\)\
\-\ at\\:\\ 0\\.0008864955228419855\ \(0\)\
\-\ year\\:\\ 0\\.0007320867299180052\ \(0\)\
